DK2618814T3 - Caspofunginsammensætning - Google Patents
Caspofunginsammensætning Download PDFInfo
- Publication number
- DK2618814T3 DK2618814T3 DK11761049.3T DK11761049T DK2618814T3 DK 2618814 T3 DK2618814 T3 DK 2618814T3 DK 11761049 T DK11761049 T DK 11761049T DK 2618814 T3 DK2618814 T3 DK 2618814T3
- Authority
- DK
- Denmark
- Prior art keywords
- caspofungin
- composition
- pharmaceutically acceptable
- buffering agent
- solution
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 106
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims description 68
- 229960003034 caspofungin Drugs 0.000 claims description 66
- 108010020326 Caspofungin Proteins 0.000 claims description 57
- 239000000243 solution Substances 0.000 claims description 43
- 239000006172 buffering agent Substances 0.000 claims description 35
- 238000009472 formulation Methods 0.000 claims description 25
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000004108 freeze drying Methods 0.000 claims description 18
- 239000012931 lyophilized formulation Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 13
- 229930006000 Sucrose Natural products 0.000 claims description 13
- 159000000021 acetate salts Chemical class 0.000 claims description 13
- 239000005720 sucrose Substances 0.000 claims description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 238000007911 parenteral administration Methods 0.000 claims description 10
- 150000003890 succinate salts Chemical group 0.000 claims description 10
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 206010017533 Fungal infection Diseases 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 5
- 208000031888 Mycoses Diseases 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000003385 bacteriostatic effect Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 241000228212 Aspergillus Species 0.000 claims description 3
- 241000228197 Aspergillus flavus Species 0.000 claims description 3
- 241001225321 Aspergillus fumigatus Species 0.000 claims description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 3
- 241000222122 Candida albicans Species 0.000 claims description 3
- 241000222178 Candida tropicalis Species 0.000 claims description 3
- 240000002355 Celtis tournefortii var. glabrata Species 0.000 claims description 3
- 241000235645 Pichia kudriavzevii Species 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000008223 sterile water Substances 0.000 claims description 3
- 241000228245 Aspergillus niger Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000012535 impurity Substances 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 14
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 239000007857 degradation product Substances 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000008351 acetate buffer Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000001384 succinic acid Substances 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000012430 stability testing Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010049047 Echinocandins Proteins 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229940080858 cancidas Drugs 0.000 description 2
- JYIKNQVWKBUSNH-OGZDCFRISA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-OGZDCFRISA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241001460671 Glarea lozoyensis Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012871 anti-fungal composition Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000009112 empiric therapy Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000009085 invasive aspergillosis Diseases 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38433310P | 2010-09-20 | 2010-09-20 | |
| PCT/EP2011/066202 WO2012038371A1 (en) | 2010-09-20 | 2011-09-19 | Caspofungin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2618814T3 true DK2618814T3 (en) | 2016-10-10 |
Family
ID=44677877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11761049.3T DK2618814T3 (en) | 2010-09-20 | 2011-09-19 | Caspofunginsammensætning |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20120101030A1 (enExample) |
| EP (1) | EP2618814B1 (enExample) |
| JP (1) | JP5914486B2 (enExample) |
| KR (1) | KR20130136466A (enExample) |
| CN (1) | CN103118663A (enExample) |
| AU (1) | AU2011304408B2 (enExample) |
| CA (1) | CA2810112A1 (enExample) |
| DK (1) | DK2618814T3 (enExample) |
| ES (1) | ES2593727T3 (enExample) |
| HR (1) | HRP20161236T1 (enExample) |
| HU (1) | HUE030464T2 (enExample) |
| IL (1) | IL225339A0 (enExample) |
| MX (1) | MX2013003045A (enExample) |
| PL (1) | PL2618814T3 (enExample) |
| PT (1) | PT2618814T (enExample) |
| RS (1) | RS55216B1 (enExample) |
| RU (1) | RU2013114993A (enExample) |
| UA (1) | UA111599C2 (enExample) |
| WO (1) | WO2012038371A1 (enExample) |
| ZA (1) | ZA201302113B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103212059A (zh) * | 2012-01-18 | 2013-07-24 | 江苏恒瑞医药股份有限公司 | 含有抗真菌药物和乳酸盐缓冲液的组合物 |
| CN103212058A (zh) * | 2012-01-18 | 2013-07-24 | 江苏恒瑞医药股份有限公司 | 含有抗真菌药物和乳酸盐缓冲剂的组合物 |
| CA2888625A1 (en) | 2012-11-20 | 2014-05-30 | Fresenius Kabi Usa, Llc | Caspofungin acetate formulations |
| CN103142997A (zh) * | 2013-03-13 | 2013-06-12 | 浙江海正药业股份有限公司 | 含有抗真菌剂和琥珀酸盐缓冲液的药物组合物 |
| KR20140123782A (ko) * | 2013-04-15 | 2014-10-23 | 에스케이케미칼주식회사 | 카스포펀진 및 완충제를 포함하는 안정성이 개선된 약학적 조성물 |
| CN104116716A (zh) * | 2013-04-25 | 2014-10-29 | 四川海思科制药有限公司 | 一种含卡泊芬净的冻干粉针剂药物组合物 |
| WO2015052115A1 (en) * | 2013-10-07 | 2015-04-16 | Galenicum Health S.L. | Stable pharmaceutical formulations of caspofungin |
| GR1008818B (el) * | 2015-05-22 | 2016-08-01 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου |
| CN108760937B (zh) * | 2018-07-27 | 2020-12-29 | 杭州华东医药集团新药研究院有限公司 | 醋酸卡泊芬净中残留乙二胺的测定及其应用 |
| CN109758426B (zh) * | 2019-01-24 | 2021-04-27 | 四川制药制剂有限公司 | 一种注射用醋酸卡泊芬净药物组合物及其制备方法 |
| CN110859950B (zh) * | 2019-11-25 | 2021-08-10 | 武汉大学 | 一种用于白念珠菌棘白菌素类药物耐药菌的药物组合物及其应用 |
| EP4364566A1 (en) * | 2022-11-04 | 2024-05-08 | B. Braun Melsungen AG | Anti-fungal composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7673991A (en) * | 1990-03-30 | 1991-10-30 | Smithkline Beecham Corporation | Method for treating fungal infection |
| US5378894A (en) | 1991-12-11 | 1995-01-03 | Kabushiki Kaisha Toshiba | X-ray detector including scintillator channel separator capable of improving sensitivity of X-ray detector |
| US5378804A (en) | 1993-03-16 | 1995-01-03 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
| US5952300A (en) | 1996-04-19 | 1999-09-14 | Merck & Co., Inc. | Antifungal compositions |
| US20080046580A1 (en) | 2006-06-29 | 2008-02-21 | Nokia Corporation | Account creation system and call processing system |
| CN101516387B (zh) * | 2006-07-26 | 2014-06-04 | 桑多斯股份公司 | 卡泊芬净制剂 |
| ES2401299T5 (es) * | 2006-07-26 | 2016-04-06 | Sandoz Ag | Formulaciones de caspofungina |
| US20100137197A1 (en) | 2007-06-26 | 2010-06-03 | Sachin Mittal | Lyophilized anti-fungal composition |
| EP2285236A1 (en) * | 2008-05-30 | 2011-02-23 | DSM IP Assets B.V. | Use of succinic acid |
| KR20110011704A (ko) | 2008-06-25 | 2011-02-08 | 테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 | 카스포펀진 불순물 ａ를 함유하지 않는 카스포펀진 |
-
2011
- 2011-09-19 RU RU2013114993/15A patent/RU2013114993A/ru not_active Application Discontinuation
- 2011-09-19 MX MX2013003045A patent/MX2013003045A/es active IP Right Grant
- 2011-09-19 RS RS20160810A patent/RS55216B1/sr unknown
- 2011-09-19 AU AU2011304408A patent/AU2011304408B2/en not_active Ceased
- 2011-09-19 UA UAA201304481A patent/UA111599C2/uk unknown
- 2011-09-19 EP EP11761049.3A patent/EP2618814B1/en active Active
- 2011-09-19 CA CA2810112A patent/CA2810112A1/en not_active Abandoned
- 2011-09-19 HR HRP20161236TT patent/HRP20161236T1/hr unknown
- 2011-09-19 HU HUE11761049A patent/HUE030464T2/en unknown
- 2011-09-19 PT PT117610493T patent/PT2618814T/pt unknown
- 2011-09-19 KR KR1020137010070A patent/KR20130136466A/ko not_active Ceased
- 2011-09-19 DK DK11761049.3T patent/DK2618814T3/en active
- 2011-09-19 PL PL11761049T patent/PL2618814T3/pl unknown
- 2011-09-19 JP JP2013528699A patent/JP5914486B2/ja not_active Expired - Fee Related
- 2011-09-19 CN CN2011800451119A patent/CN103118663A/zh active Pending
- 2011-09-19 ES ES11761049.3T patent/ES2593727T3/es active Active
- 2011-09-19 WO PCT/EP2011/066202 patent/WO2012038371A1/en not_active Ceased
- 2011-09-20 US US13/237,193 patent/US20120101030A1/en not_active Abandoned
-
2013
- 2013-03-19 IL IL225339A patent/IL225339A0/en unknown
- 2013-03-20 ZA ZA2013/02113A patent/ZA201302113B/en unknown
-
2014
- 2014-11-19 US US14/547,742 patent/US9393307B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2013114993A (ru) | 2014-10-27 |
| WO2012038371A1 (en) | 2012-03-29 |
| UA111599C2 (uk) | 2016-05-25 |
| RS55216B1 (sr) | 2017-02-28 |
| PL2618814T3 (pl) | 2017-01-31 |
| CA2810112A1 (en) | 2012-03-29 |
| EP2618814A1 (en) | 2013-07-31 |
| EP2618814B1 (en) | 2016-07-27 |
| AU2011304408B2 (en) | 2015-01-15 |
| MX2013003045A (es) | 2013-06-24 |
| AU2011304408A1 (en) | 2013-03-28 |
| HUE030464T2 (en) | 2017-05-29 |
| US9393307B2 (en) | 2016-07-19 |
| KR20130136466A (ko) | 2013-12-12 |
| CN103118663A (zh) | 2013-05-22 |
| PT2618814T (pt) | 2016-10-06 |
| ES2593727T3 (es) | 2016-12-12 |
| ZA201302113B (en) | 2014-05-28 |
| IL225339A0 (en) | 2013-06-27 |
| US20150072923A1 (en) | 2015-03-12 |
| HRP20161236T1 (hr) | 2016-11-18 |
| US20120101030A1 (en) | 2012-04-26 |
| JP5914486B2 (ja) | 2016-05-11 |
| JP2013537212A (ja) | 2013-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2618814T3 (en) | Caspofunginsammensætning | |
| EP2170362B1 (en) | Lyophilized anti-fungal composition | |
| JP4972750B2 (ja) | 非経口抗真菌生成物 | |
| JP5723030B2 (ja) | エキノカンジン系抗真菌剤であるミカファンギンを含む薬用組成物およびその製造方法と用途 | |
| KR100589878B1 (ko) | 사람 성장 호르몬을 함유한 수성 의약 조성물 | |
| WO2011035108A1 (en) | Formulations of daptomycin | |
| US20130338060A1 (en) | Liquid medicinal composition containing echinocandin antifungal agent micafungin | |
| US20140030214A1 (en) | Liquid formulation of g-csf | |
| EP3054924B1 (en) | Stable pharmaceutical formulations of caspofungin | |
| US20230068866A1 (en) | Daptomycin formulation | |
| US20140275122A1 (en) | Voriconazole Formulations | |
| EP4609874A1 (en) | Pharmaceutical composition comprising echinocandin analog and preparation method for pharmaceutical composition | |
| WO2022034545A1 (en) | Etelcalcetide formulations for parenteral use |